Brookline initiated coverage of Y-mAbs Therapeutics (YMAB) with a Buy rating and $17 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics initiated with an Outperform at Oppenheimer
- Y-mAbs Reports Third Quarter 2024 Financial Results
- Morning Movers: Expedia, Airbnb moving in opposite directions after results
- Y-mAbs Therapeutics reports Q3 EPS (16c), consensus (16c)
- Y-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M